{"id":"W2902725138","doi":"10.1016/j.euo.2018.11.005","title":"Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial","year":2018,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Janssen Biotech; Janssen Research and Development; Genentech; European Society for Medical Oncology; Astellas Pharma; Eisai; Bayer; Canada Millennium Scholarship Foundation; Phycological Society of America; Amgen; Boehringer Ingelheim; Gilead Sciences; AbbVie; Sanofi; Novartis; Bristol-Myers Squibb; AstraZeneca; Pfizer","keywords":"Enzalutamide; Medicine; Prostate cancer; Oncology; Internal medicine; Clinical trial; Randomized controlled trial; Prostate-specific antigen; Cabazitaxel; Prostate; Cancer; Androgen deprivation therapy; Androgen receptor","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00656055,0.0006825484,0.001584683,0.0002790153,0.0003474914,0.0008581313,0.0005740886,0.000868505,0.001885221],"category_scores_gemma":[0.004676453,0.0003517451,0.001353423,0.0003843892,0.0009790059,0.0006115778,0.000352891,0.0009492279,0.0001949456],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004815276,"about_ca_system_score_gemma":0.001161274,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003826215,"about_ca_topic_score_gemma":0.001069556,"domain_scores_codex":[0.9970264,0.002202938,0.0001854261,0.0002668213,0.0001920926,0.0001264445],"domain_scores_gemma":[0.9960594,0.001310534,0.00151276,0.0002894359,0.0001940361,0.0006338294],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9685347,0.002065192,0.01766987,0.0002774066,0.001191174,0.00002584016,0.00003174035,0.0002340855,0.001127878,0.00005243971,0.0001764981,0.008613109],"study_design_scores_gemma":[0.6671783,0.233559,0.09177776,0.0001230694,0.00324397,0.0001599893,0.00005554678,0.001359053,0.001301111,0.0002589239,0.0009435098,0.00003976645],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9958543,0.002419239,0.0001893443,0.0001429681,0.00005901259,0.0007205019,0.0001934083,0.00001206421,0.0004092623],"genre_scores_gemma":[0.9973028,0.0005731666,0.0005453306,0.0001633929,0.0001346892,0.0006615747,0.0004060061,0.000002794002,0.0002101835],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00656055,"threshold_uncertainty_score":0.03469592,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06802942518975472,"score_gpt":0.408579779599711,"score_spread":0.3405503544099563,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}